KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2021 - 2023)

Historic Long-Term Investments for Ginkgo Bioworks Holdings (DNA) over the last 3 years, with Q4 2023 value amounting to $78.6 million.

  • Ginkgo Bioworks Holdings' Long-Term Investments fell 2997.02% to $78.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $78.6 million, marking a year-over-year decrease of 2997.02%. This contributed to the annual value of $78.6 million for FY2023, which is 2997.02% down from last year.
  • As of Q4 2023, Ginkgo Bioworks Holdings' Long-Term Investments stood at $78.6 million, which was down 2997.02% from $85.0 million recorded in Q3 2023.
  • Ginkgo Bioworks Holdings' Long-Term Investments' 5-year high stood at $1.7 billion during Q1 2021, with a 5-year trough of $78.6 million in Q4 2023.
  • Moreover, its 3-year median value for Long-Term Investments was $103.9 million (2021), whereas its average is $371.9 million.
  • As far as peak fluctuations go, Ginkgo Bioworks Holdings' Long-Term Investments crashed by 9483.67% in 2022, and later skyrocketed by 3466.56% in 2023.
  • Quarter analysis of 3 years shows Ginkgo Bioworks Holdings' Long-Term Investments stood at $102.0 million in 2021, then rose by 9.95% to $112.2 million in 2022, then dropped by 29.97% to $78.6 million in 2023.
  • Its Long-Term Investments was $78.6 million in Q4 2023, compared to $85.0 million in Q3 2023 and $119.9 million in Q2 2023.